World Mental Health Day 2026: Why Lived Experience Now Moves Markets This Saturday, October 10, marks World Mental Health Day. The World Federation for Mental…
October 08, 2026
Rett Syndrome Awareness Month: Acadia Extends Drug Protection as Taysha Gene Therapy Nears Pivotal Data
Acadia has the first approved Rett syndrome treatment and a path to five more years of U.S. exclusivity. Taysha has finished dosing a pivotal trial…
Key Points Firefly Neuroscience will introduce NeuroSigma’s Monarch eTNS System to its nationwide network of clinicians who use the Evoke platform. Monarch is an FDA-cleared,…
Key Points Vistagen Therapeutics presented exploratory fasedienol data at Psych Congress 2026 in New Orleans. The analyses focused on participants with very severe social anxiety…
VistaGen Therapeutics (NASDAQ: VTGN) surged 53.94% to $0.387 after spiking as high as $0.5476, with trading volume exploding to roughly 498 million shares—far above its…
September 22, 2026
Vistagen Says Fasedienol Nasal Spray Showed Continued Improvement in Social Anxiety Extension Study
Key Points Vistagen released early results from a longer-term study of fasedienol nasal spray for people with social anxiety disorder. Participants could use the treatment…
Alzheimer’s disease starts long before anyone notices it. The changes in the brain that eventually show up as memory lapses, confusion or personality shifts can…
Key Points AbbVie presented new real-world VRAYLAR® results at Psych Congress 2026. Adults with major depressive disorder and bipolar I depression showed improvements in depression…
September 15, 2026
Enveric Secures New U.S. Patent Allowance for Non-Hallucinogenic PTSD Drug Candidates
Key Points Enveric Biosciences received a Notice of Allowance from the U.S. Patent and Trademark Office for compounds in its EVM401 drug-candidate series. The allowance…
Key Points Definium Therapeutics said its Phase 3 Panorama trial met its main goal and all key secondary efficacy endpoints in adults with generalized anxiety…
September 11, 2026
NRx’s HOPE Therapeutics Prepares First Robotic TMS Deployment in Florida
Key Points NRx Pharmaceuticals’ HOPE Therapeutics subsidiary is preparing to deploy Zeta Surgical’s FDA-cleared robotic transcranial magnetic stimulation, or TMS, system in Florida clinics. HOPE…
September 08, 2026
Compass Pathways Launches TRD Education Campaign at Psych Congress 2026
Key Points Compass Pathways will introduce its U.S. healthcare-provider education campaign, Change the Tune in TRD, at Psych Congress 2026 in New Orleans. The campaign focuses…